Two workers in pharmaceutical business sporting protecting gloves, masks, cap and white go well with seen standing by the machine that’s the a part of the medicaments manufacturing in the course of the working hours in a pharmaceutical manufacturing.
Excessive-photographer | E+ | Getty Photos
A multitude of things are coming collectively to convey a giant burst in biotech M&A.
The high-profile bidding conflict between Pfizer and Novo Nordisk over Metsera and its main weight reduction drug candidate exhibits simply how aggressive some pockets of the sector have develop into, as Massive Pharma frantically works to fill the looming income gap.
A number of the best-selling medicine on the earth are dealing with a lack of exclusivity in key jurisdictions in what the sector calls “the patent cliff.” By 2032, losses of exclusivity for best-selling manufacturers are value a minimum of $173.9 billion in annual gross sales, in line with CNBC calculations. Estimates differ on the overall quantity of income in danger when factoring in smaller manufacturers, with some analysts placing the quantity between $200 billion and $350 billion.
That poses an actual menace to their makers’ prime traces — except they handle to replenish their pipelines with new, revenue-bearing improvements.
The necessity for pharma to prime up their pipelines coincides with the broader biotech sector coming again to life after years of depressed valuations following a growth in healthcare investing in the course of the Covid-19 pandemic.
M&A within the sector picked up dramatically in September and October 2025, following a horrible begin to the 12 months. The lifting of overhangs from Trump’s conflict on excessive drug costs for Individuals and threats of triple-digit pharma sector tariffs, in addition to the start of an interest-rate slicing cycle, has additional inspired dealmaking.
Now, firms are dealing with a scenario the place they should fill their pipelines, whereas additionally navigating a aggressive surroundings for the very best property.
Filling the income gap
The biopharma sector is exclusive in that firms face a lack of patent for lead property each decade or so. That lifecycle of property requires firms to continuously provide you with new improvements – or purchase those that do.
“Biotech, being the innovation form of engine of healthcare, is the place pharmaceutical firms have come traditionally to construct their biopharma companies,” Linden Thomson, senior portfolio supervisor at Candriam, instructed CNBC.
Pharmaceutical companies, a lot of which began as chemical firms, sometimes constructed their companies on less complicated, small molecule medicine, whereas biotechs use dwelling organisms to make medicines like antibodies and mRNA. Over time, the excellence between the 2 has blurred as pharma invested closely in biotech and most of the medicine available on the market at present had been as a substitute found by biotech firms or concerned with biotech manufacturing, Thomson mentioned.
The looming patent cliff, which incorporates the lack of exclusivity on Bristol Myers Squibb’s Eliquis, Merck’s Keytruda, and Novo Nordisk’s Ozempic, is a driving drive behind M&A and a key a part of many large-cap pharma firms’ enterprise technique.
Based on evaluation by healthcare market researcher and advisor Joanna Sadowska, about half of the blockbuster medicine authorized between 2014 and 2023 had been purchased, versus being developed internally. The 2 most profitable drugmakers by way of the variety of blockbusters authorized over these years had been Eli Lilly and AstraZeneca, which acquired eight and 5 medicines out of a complete of 13, respectively.
European heavyweights GSK and Novartis are amongst these clear about the necessity to add to their pipelines via offers. Each are searching for what they name “bolt-on offers” that slot in with their key therapeutic and expertise areas.
Throughout an investor occasion in London in November, Novartis CEO Vasant Narasimhan emphasised the corporate’s robust money era “that basically permits us to spend money on the enterprise.”
Whereas Novartis would not put a dimension on these bolt-on offers, having carried out offers of as much as $12 billion, GSK is extra particular.
Chris Sheldon, international head of enterprise improvement at GSK, calls it the “candy spot”: going after validated biology, usually in mid-stage improvement within the $1 billion to $2 billion vary, the place the result of a drug candidate is not but apparent. Many acquisitions of late-stage property find yourself turning into a maths downside, Sheldon instructed CNBC, notably if it is a listed firm that has reached honest worth.
“BD [Business development] I at all times describe as a contact sport. If an asset is nice sufficient, there’s a number of suitors,” he added.
Offers can vary from partnerships and licensing and royalties agreements to clear-cut buyouts.
“We’d do licensing day by day of the week versus M&A if we may, as a result of you’ll be able to handle danger and reward the accomplice as worth is unlocked and danger is discharged,” Sheldon mentioned.
Nonetheless, an acquisition with a giant price ticket paid up entrance might at occasions be the one choice, and it might have some engaging advantages, equivalent to taking complete management of the event plans and buying expertise in addition to the molecules. “The truth is definitely the vendor usually dictates that, lots of people do not understand that,” Sheldon mentioned.
A aggressive surroundings
As biotech M&A grew to become scorching once more, November noticed arguably the sector’s most dramatic occasion of the 12 months happen: the general public bidding conflict between Pfizer and Novo Nordisk over clinical-stage weight reduction drug maker Metsera, finally received by Pfizer in a deal value as much as $10 billion.
It is uncommon for bidding to happen within the public eye, mentioned Stefan Loren, managing director at Oppenheimer. “It is a very public factor to chase an organization, and so it’s a must to fear in regards to the reputational injury: A, if you happen to lose; B: if you happen to get too exuberant and go to purchase,” he instructed CNBC.
“That undoubtedly says one thing in regards to the biotech market and corporations eager to play catch-up,” Loren added. “They’re responding to what their scenario is, their scenario is that they are about to have lots of issues come off patent.”
[Business development] I at all times describe as a contact sport. If an asset is nice sufficient, there’s a number of suitors.
Chris Sheldon
International head of enterprise improvement at GSK
Usually, pharma procuring sprees have a tendency to last as long as a 12 months and a half earlier than pulling again, Loren added.
The GLP-1 marketplace for weight reduction medicine has develop into one of the crucial aggressive segments in international pharma as main gamers race to safe next-generation property via each inner improvement and acquisitions, famous PitchBook researchers of their 2026 Healthcare outlook printed early December. Greater than 120 metabolic property are at present in improvement throughout 60 firms, making a deep pool of potential M&A targets, they added.
“The high-profile battle between Pfizer and Novo Nordisk for Metsera underscores the escalating strategic urgency on this house,” they mentioned. “We count on competitors to accentuate as differentiation home windows slim and coverage tailwinds increase reimbursement and regulatory help.”
Whereas the weight problems house lends itself effectively as an example present aggressive dynamics, the biotech growth is not confined to 1 single therapeutic space. Neurology, oncology, immunology, and irritation are different key areas of exercise.
“It is idiosyncratic what’s in style at any given level,” mentioned Loren. “They [companies] are going for what can fill the pipelines as shortly as doable.”
A growth, dip and one other growth
Throughout the Covid-19 pandemic, biotech sailed to the highest of buyers’ wishlists. Amid elevated consideration, buyers’ optimism, and low rates of interest, the sector flourished, valuations skyrocketed, and plenty of biotech firms went public or had been purchased by bigger friends.
Because the biopharma business is a cost-intensive analysis enterprise, elevating cash is crucial for drug discovery. Early-stage biotechs function with excessive stakes, usually making them early casualties of a risk-off market just like the one following the pandemic growth.
All through a lot of 2025, the Trump administration additionally clouded the outlook for biopharma with threats of excessive sector tariffs, cuts to federal well being businesses, and decrease drug costs. However as firms have made offers with Trump on pricing and the president has made clear that in the event that they spend money on U.S. manufacturing, they might be exempt from extra tariffs — two large overhangs for the sector have cleared.
A flurry of fine information readouts has additionally boosted biotech valuations, mentioned Loren. Solely a 12 months in the past, even good information despatched shares down, he mentioned. “Individuals had been utilizing every thing as an occasion simply to get out.”
By late spring, the market began to shift and now, buyers take good information and run with it. “There is a level at which these items get so low that on the finish of the day, what is the danger?” Loren mentioned. “And now, once we noticed the acceleration of M&A, the excellent news is that that play grew to become very actual.”
Extra offers in 2026
In 2026, offers may choose up even additional, analysts say.
“We see 2026 as offering top-of-the-line investing alternatives now we have seen in many years,” the PitchBook analysts mentioned, pushed by the clearing of U.S. healthcare coverage overhangs and extra charge cuts spurring extra speculative investing postures.
Rajesh Kumar, head of European life sciences and healthcare fairness analysis at HSBC, equally expects a “large ramp up of deal flows” within the 12 months forward now that the noise round drug pricing has settled.
“The market’s margin expectations past [2026] may be a bit extra optimistic than it needs to be, however nonetheless, the businesses are deploying capital within the U.S., manufacturing is occurring, readability is there, and that could be a nice surroundings for really doing biotech offers and early stage biotech funding,” he instructed CNBC’s “Squawk Field Europe.”
Different developments within the pharma sector may make for one more 12 months of great headwinds – probably including to the urgency for drugmakers to make offers.
Costs for sure bestselling medicine will begin to come down beneath the U.S. Inflation Discount Act in 2026, which seems to deal with the energetic ingredient of medicine by the identical producer as the identical, limiting life cycle administration choices in some instances, HSBC analysts mentioned. Biosimilars within the U.S. may additionally develop into simpler to launch if a current Meals and Drug Administration draft steering is carried out.
“All these elements would possibly imply that the fade past the patent cliffs, particularly for biologics, may be extra aggressive than up to now,” the analysts mentioned.
